EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The use of biosimilar insulins in 2023

Sarah Monsonego

Canadian Diabetes & Endocrinology Today · 2023

DOI: 10.58931/cdet.2023.118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, 2023. Verfasst von Sarah Monsonego. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A biosimilar is a drug that is highly similar to a biologic drug and has been shown to have no clinically meaningful difference from its originator drug despite minor differences in clinically inactive components. In light of the increasing rates of diabetes and costs to the Canadian healthcare system, the use of biosimilar insulins is intended to increase the affordability of biologics. This article will review the available biosimilars approved in Canada, safety and efficacy studies, and the advantages and potential concerns regarding the switch to biosimilar insulins.

Zitieren

APA

Monsonego, S. (2023). The use of biosimilar insulins in 2023. Canadian Diabetes & Endocrinology Today. https://doi.org/10.58931/cdet.2023.118

Vancouver

Monsonego S. The use of biosimilar insulins in 2023. Canadian Diabetes & Endocrinology Today. 2023. doi:10.58931/cdet.2023.118

BibTeX
@article{Monsonego2023,
  author = {Monsonego, Sarah},
  title = {The use of biosimilar insulins in 2023},
  journal = {Canadian Diabetes & Endocrinology Today},
  year = {2023},
  doi = {10.58931/cdet.2023.118}
}
Kostenlos starten →